APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lipid Nanoparticle (LNP) CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lipid Nanoparticle (LNP) CDMO Service Market Outlook and Growth Opportunities 2026

15 January 2026210 pages

Choose your research edition.

Industry ResearchLipid Nanoparticle (LNP) CDMO Service Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Lipid Nanoparticle (LNP) CDMO Service Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Lipid Nanoparticle (LNP) CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lipid Nanoparticle (LNP) CDMO Service Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Lipid Nanoparticle (LNP) CDMO Service Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Lipid Nanoparticle (LNP) CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lipid Nanoparticle (LNP) CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lipid Nanoparticle (LNP) CDMO Service market include Evonik, Helix Biotech, FUJIFILM Holdings, Merck, Ascendia Pharmaceuticals, Catalent, Polymun Scientific, Genevant Sciences and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lipid Nanoparticle (LNP) CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lipid Nanoparticle (LNP) CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lipid Nanoparticle (LNP) CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lipid Nanoparticle (LNP) CDMO Service market.

Lipid Nanoparticle (LNP) CDMO Service Segment by Company

Evonik

Helix Biotech

FUJIFILM Holdings

Merck

Ascendia Pharmaceuticals

Catalent

Polymun Scientific

Genevant Sciences

Cytiva

Croda International

Nippon Fine Chemical

Patheon

Biomay

Pace Analytical

CordenPharma

Vernal Biosciences

Lonza

Acuitas Therapeutics

Creative Biolabs

WuXi STA

GenScript

MicroNano Biologics

Lipid Nanoparticle (LNP) CDMO Service Segment by Type

Formulation Development

cGMP Manufacturing

Others

Lipid Nanoparticle (LNP) CDMO Service Segment by Application

Vaccine Development

Gene Therapy

Drug Delivery

Others

Lipid Nanoparticle (LNP) CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lipid Nanoparticle (LNP) CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lipid Nanoparticle (LNP) CDMO Service key companies, revenue, market share, and recent developments.

3. To split the Lipid Nanoparticle (LNP) CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lipid Nanoparticle (LNP) CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lipid Nanoparticle (LNP) CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze Lipid Nanoparticle (LNP) CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid Nanoparticle (LNP) CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lipid Nanoparticle (LNP) CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid Nanoparticle (LNP) CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lipid Nanoparticle (LNP) CDMO Service industry.

Chapter 3: Detailed analysis of Lipid Nanoparticle (LNP) CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lipid Nanoparticle (LNP) CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lipid Nanoparticle (LNP) CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lipid Nanoparticle (LNP) CDMO Service Industry Trends Table 2. Lipid Nanoparticle (LNP) CDMO Service Industry Drivers Table 3. Lipid Nanoparticle (LNP) CDMO Service Industry Opportunities and Challenges Table 4. Lipid Nanoparticle (LNP) CDMO Service Industry Restraints Table 5. Global Lipid Nanoparticle (LNP) CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lipid Nanoparticle (LNP) CDMO Service Revenue Share by Company (2021-2026) Table 7. Global Lipid Nanoparticle (LNP) CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lipid Nanoparticle (LNP) CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global Lipid Nanoparticle (LNP) CDMO Service Company, Product Type & Application Table 10. Global Lipid Nanoparticle (LNP) CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lipid Nanoparticle (LNP) CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Formulation Development Table 15. Significant Companies of cGMP Manufacturing Table 16. Significant Companies of Others Table 17. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type (2021-2026) Table 21. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Vaccine Development Table 23. Significant Companies of Gene Therapy Table 24. Significant Companies of Drug Delivery Table 25. Significant Companies of Others Table 26. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application (2021-2026) Table 30. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application (2027-2032) Table 31. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Region (2021-2026) Table 34. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Region (2027-2032) Table 36. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Market Share by Country (2021-2026) Table 39. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Market Share by Country (2027-2032) Table 41. Evonik Company Information Table 42. Evonik Business Overview Table 43. Evonik Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Evonik Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 45. Evonik Recent Development Table 46. Helix Biotech Company Information Table 47. Helix Biotech Business Overview Table 48. Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 50. Helix Biotech Recent Development Table 51. FUJIFILM Holdings Company Information Table 52. FUJIFILM Holdings Business Overview Table 53. FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 55. FUJIFILM Holdings Recent Development Table 56. Merck Company Information Table 57. Merck Business Overview Table 58. Merck Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Merck Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 60. Merck Recent Development Table 61. Ascendia Pharmaceuticals Company Information Table 62. Ascendia Pharmaceuticals Business Overview Table 63. Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 65. Ascendia Pharmaceuticals Recent Development Table 66. Catalent Company Information Table 67. Catalent Business Overview Table 68. Catalent Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Catalent Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 70. Catalent Recent Development Table 71. Polymun Scientific Company Information Table 72. Polymun Scientific Business Overview Table 73. Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 75. Polymun Scientific Recent Development Table 76. Genevant Sciences Company Information Table 77. Genevant Sciences Business Overview Table 78. Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 80. Genevant Sciences Recent Development Table 81. Cytiva Company Information Table 82. Cytiva Business Overview Table 83. Cytiva Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Cytiva Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 85. Cytiva Recent Development Table 86. Croda International Company Information Table 87. Croda International Business Overview Table 88. Croda International Lipid Nanoparticle (LNP) CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Croda International Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 90. Croda International Recent Development Table 91. Nippon Fine Chemical Company Information Table 92. Nippon Fine Chemical Business Overview Table 93. Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 95. Nippon Fine Chemical Recent Development Table 96. Patheon Company Information Table 97. Patheon Business Overview Table 98. Patheon Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Patheon Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 100. Patheon Recent Development Table 101. Biomay Company Information Table 102. Biomay Business Overview Table 103. Biomay Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Biomay Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 105. Biomay Recent Development Table 106. Pace Analytical Company Information Table 107. Pace Analytical Business Overview Table 108. Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 110. Pace Analytical Recent Development Table 111. CordenPharma Company Information Table 112. CordenPharma Business Overview Table 113. CordenPharma Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. CordenPharma Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 115. CordenPharma Recent Development Table 116. Vernal Biosciences Company Information Table 117. Vernal Biosciences Business Overview Table 118. Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 120. Vernal Biosciences Recent Development Table 121. Lonza Company Information Table 122. Lonza Business Overview Table 123. Lonza Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Lonza Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 125. Lonza Recent Development Table 126. Acuitas Therapeutics Company Information Table 127. Acuitas Therapeutics Business Overview Table 128. Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 130. Acuitas Therapeutics Recent Development Table 131. Creative Biolabs Company Information Table 132. Creative Biolabs Business Overview Table 133. Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 135. Creative Biolabs Recent Development Table 136. WuXi STA Company Information Table 137. WuXi STA Business Overview Table 138. WuXi STA Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. WuXi STA Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 140. WuXi STA Recent Development Table 141. GenScript Company Information Table 142. GenScript Business Overview Table 143. GenScript Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. GenScript Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 145. GenScript Recent Development Table 146. MicroNano Biologics Company Information Table 147. MicroNano Biologics Business Overview Table 148. MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio Table 150. MicroNano Biologics Recent Development Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Lipid Nanoparticle (LNP) CDMO Service Product Image Figure 2. Global Lipid Nanoparticle (LNP) CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lipid Nanoparticle (LNP) CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Lipid Nanoparticle (LNP) CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Formulation Development Image Figure 8. cGMP Manufacturing Image Figure 9. Others Image Figure 10. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type (2021-2032) Figure 13. Vaccine Development Image Figure 14. Gene Therapy Image Figure 15. Drug Delivery Image Figure 16. Others Image Figure 17. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application (2021-2032) Figure 20. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Formulation Development
  • cGMP Manufacturing
  • Others
Applications
  • Vaccine Development
  • Gene Therapy
  • Drug Delivery
  • Others
Companies covered
  • Evonik
  • Helix Biotech
  • FUJIFILM Holdings
  • Merck
  • Ascendia Pharmaceuticals
  • Catalent
  • Polymun Scientific
  • Genevant Sciences
  • Cytiva
  • Croda International
  • Nippon Fine Chemical
  • Patheon
  • Biomay
  • Pace Analytical
  • CordenPharma
  • Vernal Biosciences
  • Lonza
  • Acuitas Therapeutics
  • Creative Biolabs
  • WuXi STA
  • GenScript
  • MicroNano Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lipid Nanoparticle (LNP) CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lipid Nanoparticle (LNP) CDMO Service Market Dynamics
  1. 2.1 Lipid Nanoparticle (LNP) CDMO Service Industry Trends
  2. 2.2 Lipid Nanoparticle (LNP) CDMO Service Industry Drivers
  3. 2.3 Lipid Nanoparticle (LNP) CDMO Service Industry Opportunities and Challenges
  4. 2.4 Lipid Nanoparticle (LNP) CDMO Service Industry Restraints
3 Lipid Nanoparticle (LNP) CDMO Service Market by Company
  1. 3.1 Global Lipid Nanoparticle (LNP) CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global Lipid Nanoparticle (LNP) CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global Lipid Nanoparticle (LNP) CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global Lipid Nanoparticle (LNP) CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Lipid Nanoparticle (LNP) CDMO Service Company Product Type and Application
  6. 3.6 Global Lipid Nanoparticle (LNP) CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lipid Nanoparticle (LNP) CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lipid Nanoparticle (LNP) CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lipid Nanoparticle (LNP) CDMO Service Market by Type
  1. 4.1 Lipid Nanoparticle (LNP) CDMO Service Type Introduction
  2. 4.1.1 Formulation Development
  3. 4.1.2 cGMP Manufacturing
  4. 4.1.3 Others
  5. 4.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type
  6. 4.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type (2021-2032)
5 Lipid Nanoparticle (LNP) CDMO Service Market by Application
  1. 5.1 Lipid Nanoparticle (LNP) CDMO Service Application Introduction
  2. 5.1.1 Vaccine Development
  3. 5.1.2 Gene Therapy
  4. 5.1.3 Drug Delivery
  5. 5.1.4 Others
  6. 5.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application
  7. 5.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application (2021-2032)
6 Lipid Nanoparticle (LNP) CDMO Service Regional Value Analysis
  1. 6.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Country, 2025 VS 2032
7 Lipid Nanoparticle (LNP) CDMO Service Country-level Value Analysis
  1. 7.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lipid Nanoparticle (LNP) CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Evonik
  2. 8.1.1 Evonik Company Information
  3. 8.1.2 Evonik Business Overview
  4. 8.1.3 Evonik Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Evonik Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  6. 8.1.5 Evonik Recent Developments
  7. 8.2 Helix Biotech
  8. 8.2.1 Helix Biotech Company Information
  9. 8.2.2 Helix Biotech Business Overview
  10. 8.2.3 Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  12. 8.2.5 Helix Biotech Recent Developments
  13. 8.3 FUJIFILM Holdings
  14. 8.3.1 FUJIFILM Holdings Company Information
  15. 8.3.2 FUJIFILM Holdings Business Overview
  16. 8.3.3 FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  18. 8.3.5 FUJIFILM Holdings Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Ascendia Pharmaceuticals
  26. 8.5.1 Ascendia Pharmaceuticals Company Information
  27. 8.5.2 Ascendia Pharmaceuticals Business Overview
  28. 8.5.3 Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  30. 8.5.5 Ascendia Pharmaceuticals Recent Developments
  31. 8.6 Catalent
  32. 8.6.1 Catalent Company Information
  33. 8.6.2 Catalent Business Overview
  34. 8.6.3 Catalent Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Catalent Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  36. 8.6.5 Catalent Recent Developments
  37. 8.7 Polymun Scientific
  38. 8.7.1 Polymun Scientific Company Information
  39. 8.7.2 Polymun Scientific Business Overview
  40. 8.7.3 Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  42. 8.7.5 Polymun Scientific Recent Developments
  43. 8.8 Genevant Sciences
  44. 8.8.1 Genevant Sciences Company Information
  45. 8.8.2 Genevant Sciences Business Overview
  46. 8.8.3 Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  48. 8.8.5 Genevant Sciences Recent Developments
  49. 8.9 Cytiva
  50. 8.9.1 Cytiva Company Information
  51. 8.9.2 Cytiva Business Overview
  52. 8.9.3 Cytiva Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cytiva Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  54. 8.9.5 Cytiva Recent Developments
  55. 8.10 Croda International
  56. 8.10.1 Croda International Company Information
  57. 8.10.2 Croda International Business Overview
  58. 8.10.3 Croda International Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Croda International Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  60. 8.10.5 Croda International Recent Developments
  61. 8.11 Nippon Fine Chemical
  62. 8.11.1 Nippon Fine Chemical Company Information
  63. 8.11.2 Nippon Fine Chemical Business Overview
  64. 8.11.3 Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  66. 8.11.5 Nippon Fine Chemical Recent Developments
  67. 8.12 Patheon
  68. 8.12.1 Patheon Company Information
  69. 8.12.2 Patheon Business Overview
  70. 8.12.3 Patheon Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Patheon Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  72. 8.12.5 Patheon Recent Developments
  73. 8.13 Biomay
  74. 8.13.1 Biomay Company Information
  75. 8.13.2 Biomay Business Overview
  76. 8.13.3 Biomay Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biomay Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  78. 8.13.5 Biomay Recent Developments
  79. 8.14 Pace Analytical
  80. 8.14.1 Pace Analytical Company Information
  81. 8.14.2 Pace Analytical Business Overview
  82. 8.14.3 Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  84. 8.14.5 Pace Analytical Recent Developments
  85. 8.15 CordenPharma
  86. 8.15.1 CordenPharma Company Information
  87. 8.15.2 CordenPharma Business Overview
  88. 8.15.3 CordenPharma Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CordenPharma Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  90. 8.15.5 CordenPharma Recent Developments
  91. 8.16 Vernal Biosciences
  92. 8.16.1 Vernal Biosciences Company Information
  93. 8.16.2 Vernal Biosciences Business Overview
  94. 8.16.3 Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  96. 8.16.5 Vernal Biosciences Recent Developments
  97. 8.17 Lonza
  98. 8.17.1 Lonza Company Information
  99. 8.17.2 Lonza Business Overview
  100. 8.17.3 Lonza Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Lonza Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  102. 8.17.5 Lonza Recent Developments
  103. 8.18 Acuitas Therapeutics
  104. 8.18.1 Acuitas Therapeutics Company Information
  105. 8.18.2 Acuitas Therapeutics Business Overview
  106. 8.18.3 Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  108. 8.18.5 Acuitas Therapeutics Recent Developments
  109. 8.19 Creative Biolabs
  110. 8.19.1 Creative Biolabs Company Information
  111. 8.19.2 Creative Biolabs Business Overview
  112. 8.19.3 Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  114. 8.19.5 Creative Biolabs Recent Developments
  115. 8.20 WuXi STA
  116. 8.20.1 WuXi STA Company Information
  117. 8.20.2 WuXi STA Business Overview
  118. 8.20.3 WuXi STA Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  119. 8.20.4 WuXi STA Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  120. 8.20.5 WuXi STA Recent Developments
  121. 8.21 GenScript
  122. 8.21.1 GenScript Company Information
  123. 8.21.2 GenScript Business Overview
  124. 8.21.3 GenScript Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  125. 8.21.4 GenScript Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  126. 8.21.5 GenScript Recent Developments
  127. 8.22 MicroNano Biologics
  128. 8.22.1 MicroNano Biologics Company Information
  129. 8.22.2 MicroNano Biologics Business Overview
  130. 8.22.3 MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Revenue and Gross Margin (2021-2026)
  131. 8.22.4 MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
  132. 8.22.5 MicroNano Biologics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst